PR Newswire
DUBLIN , Nov. 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place Nov. 10-14, 2021 . The poster will include data from the ION-01 study, a phase 2 trial evaluating intravenous nemvaleukin in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma that had previously progressed on an anti-PD-(L)1 therapy.
Details of the presentation are as follows:
Abstract: 432
Title: Nemvaleukin alfa, a novel engineered IL-2 cytokine, in combination with the anti-PD-1 antibody pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma (ION-01 study)
Presenter: Brian Gastman , M.D., Surgical Director, Melanoma & High-Risk Skin Cancer Program at the Cleveland Clinic, Cleveland, Ohio
Presentation Date: The poster and presentation will be available on the SITC virtual meeting platform beginning Nov. 12, 2021 . The poster is scheduled to be presented onsite at the meeting on Nov. 13, 2021 .
About Nemvaleukin Alfa ("nemvaleukin")
Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by selectively binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.
About the Nemvaleukin Clinical Development Program
ARTISTRY is an Alkermes-sponsored clinical development program evaluating nemvaleukin as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous and subcutaneous dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) in patients with advanced solid tumors. Ongoing trials in the ARTISTRY program include: ARTISTRY-1 , ARTISTRY-2 , ARTISTRY-3 , ARTISTRY-6 and ARTISTRY-7 .
ION-01 is a phase 2 trial being conducted in collaboration with Fred Hutchinson Cancer Research Center and is designed to estimate the response rate to intravenous nemvaleukin in combination with the anti-PD-1 therapy pembrolizumab in patients with advanced or recurrent head and neck squamous cell carcinoma who did not achieve complete remission with an anti-PD-(L)1 antibody treatment.
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland , Alkermes plc has an R&D center in Waltham, Massachusetts ; a research and manufacturing facility in Athlone, Ireland ; and a manufacturing facility in Wilmington, Ohio . For more information, please visit Alkermes' website at www.alkermes.com .
KEYTRUDA ® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ , USA.
Alkermes Contacts:
For Investors: Sandy Coombs , +1 781 609 6377
For Media: Sourojit Bhowmick, Ph.D., +1 781 609 6397
SOURCE Alkermes plc